Palvella Therapeutics, Inc. PVLA
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +39.80%
- 1 year
- +83.28%
- Open
- 145.04
- Prev close
- 146.15
- Mkt cap
- 2.11B
- Vol
- 303.46K
- Avg vol
- 214.17K
- EPS
- -4.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 141.98
- High
- 150.00
- Forward P/E
- -18.51
- Beta
- 0.00
- Short ratio
- 9.92
- Inst. own
- 105.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 141.47
- 200-d avg
- 126.93
- 1y target
- 228.40
News
4 days ago globenewswire.com
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
5 days ago globenewswire.com
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and…
1 week ago marketbeat.com
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
Palvella Therapeutics NASDAQ: PVLA is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt…
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
2 weeks ago globenewswire.com
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
2 weeks ago globenewswire.com
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
3 weeks ago benzinga.com
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.
1 month ago seekingalpha.com
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and FDA rolling review. Regulatory risk is now…
-
1 month ago benzinga.com
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
The award follows FDA review of Palvella’s annual performance progress report, which included results from the Phase 3 SELVA trial. In February 2026, Palvella announced positive topline results from…
1 month ago globenewswire.com
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved
1 month ago globenewswire.com
Palvella Therapeutics Appoints James R. Treat, M.D.
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
2 months ago globenewswire.com
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
2 months ago globenewswire.com
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with…
2 months ago defenseworld.net
Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA
Bank of America Corp DE grew its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 25.4% during the first quarter, according to the company in its most recent disclosure with the SEC.…
2 months ago seekingalpha.com
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel
Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and…
2 months ago marketbeat.com
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN…
2 months ago defenseworld.net
Palvella Therapeutics Q2 Earnings Call Highlights
Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second…
2 months ago globenewswire.com
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…
3 months ago seekingalpha.com
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
3 months ago marketbeat.com
Palvella Therapeutics Q2 Earnings Call Highlights
Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half…
3 months ago benzinga.com
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
-
3 months ago benzinga.com
Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over…
3 months ago globenewswire.com
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing…
3 months ago defenseworld.net
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA
Arete Wealth Advisors LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ: PVLA) during the first quarter, according to the company in its most recent 13F filing with the Securities…
3 months ago globenewswire.com
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective…
3 months ago benzinga.com
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guidance. Other gainers: UTZ, AEHR, PKE, FWRD, HELP, SECZ, DOCN, TRAX, PVLA, COIN.
-
4 months ago benzinga.com
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submittedFDA previously granted…
-
4 months ago benzinga.com
Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic Malformations
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submittedPalvella remains on…
-
5 months ago benzinga.com
Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphatic Malformations; On Track To Submit NDA In H2 Of 2026
Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking,…
-
5 months ago benzinga.com
Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For Porokeratosis
Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering…
-
5 months ago benzinga.com
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.
-
5 months ago benzinga.com
Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026
In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global…
-
5 months ago benzinga.com
Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous Malformations At Annual Meeting Of SID
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding)…
-
5 months ago benzinga.com
Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market
The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's common stock will continue to trade under its existing ticker symbol, "PVLA."The Nasdaq Global Market has…
-
5 months ago benzinga.com
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220
Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.
-
5 months ago benzinga.com
Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over…
-
6 months ago benzinga.com
Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the…
-
6 months ago benzinga.com
Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April…
-
7 months ago benzinga.com
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
-
7 months ago benzinga.com
Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over…
7 months ago benzinga.com
Earnings Scheduled For March 31, 2026
Earnings Scheduled For March 31, 2026
-
7 months ago benzinga.com
Palvella Therapeutics Publishes Comprehensive Review Article Titled Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics And Clinical Strategies
Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.
-
7 months ago benzinga.com
Palvella Therapeutics Secures European Patent Covering Lead QTORIN Rapamycin Gel
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and…
-
8 months ago benzinga.com
Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250
Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.
8 months ago benzinga.com
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday
-
8 months ago benzinga.com
BTIG Maintains Buy on Palvella Therapeutics, Raises Price Target to $215
BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $192 to $215.
-
8 months ago benzinga.com
Palvella Therapeutics Launches $150M Common Stock Offering
Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious,…
-
8 months ago benzinga.com
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $210
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $174 to $210.